These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1497 related articles for article (PubMed ID: 29801018)

  • 41. Prostate Cancer Screening.
    Mulhem E; Fulbright N; Duncan N
    Am Fam Physician; 2015 Oct; 92(8):683-8. PubMed ID: 26554408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
    Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
    Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
    JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.
    Barry MJ; Simmons LH
    Med Clin North Am; 2017 Jul; 101(4):787-806. PubMed ID: 28577627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
    Paschen U; Sturtz S; Fleer D; Lampert U; Skoetz N; Dahm P
    BJU Int; 2022 Mar; 129(3):280-289. PubMed ID: 33961337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for prostate cancer: an updated Cochrane systematic review.
    Ilic D; O'Connor D; Green S; Wilt TJ
    BJU Int; 2011 Mar; 107(6):882-91. PubMed ID: 21392207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update.
    Bennett A; Beck A; Shaver N; Grad R; LeBlanc A; Limburg H; Gray C; Abou-Setta A; Klarenbach S; Persaud N; Thériault G; Thombs BD; Todd KJ; Bell N; Dahm P; Loblaw A; Del Giudice L; Yao X; Skidmore B; Rolland-Harris E; Brouwers M; Little J; Moher D
    Syst Rev; 2022 Oct; 11(1):230. PubMed ID: 36289518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
    Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.
    Wilt TJ
    Semin Urol Oncol; 2002 Feb; 20(1):10-7. PubMed ID: 11828353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
    Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Lin JS; Perdue LA; Henrikson NB; Bean SI; Blasi PR
    JAMA; 2021 May; 325(19):1978-1998. PubMed ID: 34003220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening.
    Melnikow J; LeFevre M; Wilt TJ; Moyer VA
    Med Care; 2013 Apr; 51(4):301-3. PubMed ID: 23481031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.
    Hogenhout R; Remmers S; van Slooten-Midderigh ME; de Vos II; Roobol MJ;
    Eur Urol Oncol; 2024 Aug; 7(4):713-720. PubMed ID: 37690917
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.